Herold Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Herold Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-100	Closed	-$7K	–	252
2021 Q3	$7K	Buy	+100	New	+$7.89K	﹤0.01%	627

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Herold Advisors's BMRN Position: Q4 2021 in Review

Herold Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2021, closing a stake of 100 shares — an estimated $7K sold.

Herold Advisors first reported a position in BMRN in Q3 2021 and held it in 1 quarter. The position peaked at $7K in Q3 2021. 556 funds tracked by Wall St. Rank hold BMRN as of Q4 2021.

Herold Advisors reported no remaining BioMarin Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
Herold Advisors sold 100 BioMarin Pharmaceuticals shares in Q4 2021, an estimated $7K.
Herold Advisors first reported a position in BioMarin Pharmaceuticals in Q3 2021 and held it in 1 quarter.
Herold Advisors's BioMarin Pharmaceuticals position peaked at $7K in Q3 2021.
556 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2021.

Based on Herold Advisors's 13F filing for Q4 2021, filed 20 Jan 2022.